• 제목/요약/키워드: Covid-19 vaccine

검색결과 186건 처리시간 0.022초

Digital Technology Practices and Vaccine Campaign in Korea: International Perceptions on Health Diplomacy amid COVID-19 Crisis

  • Tahira, Iffat
    • Journal of Contemporary Eastern Asia
    • /
    • 제21권2호
    • /
    • pp.27-46
    • /
    • 2022
  • The purpose of this study is two-fold: first, to discuss the concept of health diplomacy and the Korean government's response to contain the COVID-19 pandemic; second, to assess and compare assumptions of variances about foreigners' perceptions of how Korea is leveraging digital technology in battling the coronavirus spread, and its vaccine campaign; through the lenses of Chinese, Filipino, and Pakistani foreign nationals who are currently living in Korea. A total of 219 foreigners responded to the survey. The collected data were analyzed as percentages, mean averages, t-test, and ANOVA for statistical analysis. Results show that Korea is utilizing its digital technology practices and vaccine campaign in battling the pandemic through efforts of health diplomacy. ANOVA indicated significant results and assumptions of variance across three ethnic groups showing the Pakistani population had higher mean scores than the Chinese and Filipino about Korea's health diplomacy during the pandemic. This study contributes to the literature on Korea's digital technology practices and vaccine campaigns amidst the COVID-19 pandemic by promoting its image through health diplomacy efforts. It projects the country's soft image on a global scale, to save the lives of locals and foreign nationals, by providing insights into health diplomacy in Korea.

Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19

  • Pureum Lee;Doo-Jin Kim
    • IMMUNE NETWORK
    • /
    • 제20권4호
    • /
    • pp.28.1-28.25
    • /
    • 2020
  • The recent emergence of the novel coronavirus (CoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a global threat to human health and economy. As of June 26, 2020, over 9.4 million cases of infection, including 482,730 deaths, had been confirmed across 216 countries. To combat a devastating virus pandemic, numerous studies on vaccine development are urgently being accelerated. In this review article, we take a brief look at the characteristics of SARS-CoV-2 in comparison to SARS and Middle East respiratory syndrome (MERS)-CoVs and discuss recent approaches to coronavirus disease-2019 (COVID-19) vaccine development.

항암치료를 받는 소화기 암환자에서 코로나바이러스 감염증-19 백신접종 (COVID-19 Vaccination in Patients with Gastrointestinal Cancer Receiving Chemotherapy)

  • 이종현;김동욱
    • Journal of Digestive Cancer Research
    • /
    • 제10권2호
    • /
    • pp.107-111
    • /
    • 2022
  • In 2019, coronavirus disease (COVID-19), which originated in Wuhan, has spread worldwide. In most people, COVID-19 symptoms are not severe. However, the mortality rate and severity were high in risk groups such as in older people and patients with underlying diseases. As patients with cancer are one of the risk groups, the vaccination for COVID-19 is emphasized in these patients. However, COVID-19 vaccines are not tested enough in special groups such as in patients with cancer because these vaccines are developed at an unprecedented speed. This causes confusion about whether patients undergoing chemotherapy should be vaccinated or not. In this study, international guidelines and studies were reviewed. Most of the studies recommended vaccination. No evidences of any negative effects for the efficacy or safety were recorded in patients undergoing cytotoxic, targeted, and immune agents. However, in critical conditions such as cytopenia, vaccination must be decided according to the patient's condition. COVID-19 vaccines were also recommended for patients on surgery or radiation therapy. If possible, vaccine is given before surgery to avoid confusion between surgical complications and side effects of the vaccine. The radiation recall phenomenon after vaccination has been reported in some cases of radiation therapy. Clinicians should consider these situations before vaccinating each patient. We hope that clearer guidelines will be established by accumulating verified data.

COVID-19 시대에서 외국인의 자궁경부암 백신접종 (Human Papillomavirus Vaccination for Foreigners during COVID-19 Era)

  • 임주원
    • 항공우주의학회지
    • /
    • 제31권1호
    • /
    • pp.21-23
    • /
    • 2021
  • Purpose: Human papillomavirus (HPV) vaccination schedule is recommended by Strategic Advisory Group of Experts on Immunization of World Health Organization to achieve high efficacy and immunogenicity. However, the patients often cannot keep up their schedule for several reasons. Methods: Monthly numbers of visitors for HPV vaccination between 2019 and 2021 were analyzed to measure the impact of coronavirus disease-19 (COVID-19) outbreak which was the main cause of this delay. Results: In February 2020, the number of foreign patients vaccinated with HPV was dropped suddenly due to COVID-19. Prior to this impact, the average patients per month for HPV vaccination was 160 (95% confidence interval [CI]: 143-176). It was then 30 (95% CI: 20-40). However recent trends show a gradual recovery. Conclusion: If a woman is pregnant after starting the HPV vaccine series, the reminder doses should be delayed until she is no longer pregnant. If this series is interrupted for any length of time, it can be resumed without restarting the series. HPV vaccine series need to be administered with a minimum interval of 14 days before or after administration of COVID-19 vaccines.

COVID-19 백신 투여 이후 발생한 심한 사지 자반증이 절단을 요하는 당뇨발에 미치는 영향: 증례 보고 (Effect of Severe Limb Purpura Following the Administration of COVID-19 Vaccination on a Diabetic Foot Requiring Amputation: A Case Report)

  • 김병호;서진수;장선희;최준영
    • 대한족부족관절학회지
    • /
    • 제26권1호
    • /
    • pp.48-53
    • /
    • 2022
  • The current SARS-CoV-2 coronavirus disease 2019 (COVID-19) pandemic has been a particular challenge for diabetes patients. Since these patients are at a higher risk of COVID-19, they have been prioritized for vaccination. In this report, we describe the case of a patient scheduled for diabetic foot amputation who received the first dose of ChAdOx1 nCov-19 vaccine and subsequently developed severe purpura in his genitalia and both of his hands and feet, accompanied by acute renal failure. The operation had to be postponed as severe limb purpura appeared just before the operation. With adequate management for acute renal failure and topical steroid application for the severe purpura lesions, a successful outcome could be obtained after the delayed first ray amputation. We recommend that COVID-19 vaccination should be carefully administered in patients with a diabetic foot requiring amputation.

위기상황에서 정부의 코로나 19 대책 관련 부정적 이슈의 확산 네트워크 분석 (Network analysis on the diffusion of negative issue related with the government's COVID-19 measures in a crisis situation)

  • 홍주현;차희원
    • 문화기술의 융합
    • /
    • 제8권2호
    • /
    • pp.109-116
    • /
    • 2022
  • 코로나 19 위기 상황에서 정부의 대책이 소셜미디어를 통해 어떻게 확산했는지 알아보기 위해 이 연구는 유튜브에서 코로나 19 방역과 백신 접종 관련 이슈의 확산 과정을 네트워크 분석했다. 마스크 대란, 확진자 급증, 백신 수급 문제에 대한 네트워크 분석결과 코로나 19 상황을 전달하는 언론사 채널의 영향력이 컸고, 조회 수도 높게 나타났다. 다만 보수 성향의 채널에서 감정적 헤드라인이 더 많았고, 보수 성향의 개인 채널이 정부에 대한 부정적 메시지를 확산했고 동영상 조회 수도 높게 나타났다. 정부는 소셜미디어에서 확산되는 부정적인 메시지와 허위정보에 대응하기 위해 정확한 정보를 적극적으로 알리고, 언론은 부정확한 정보, 허위정보에 대한 팩트체크를 해야 할 것이다.

Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza

  • Lee, Won Sik;Rhee, Dong-Kwon
    • Journal of Ginseng Research
    • /
    • 제45권4호
    • /
    • pp.535-537
    • /
    • 2021
  • In the 1918 influenza pandemic, more than 95% of mortalities were ascribed to bacterial pneumonia. After the primary influenza infection, the innate immune system is attenuated, and the susceptibility to bacteria is increased. Subsequent bacterial pneumonia exacerbates morbidity and increases the mortality rate. Similarly, COVID-19 infection attenuates innate immunity and results in pneumonia. In addition, the current pneumococcal conjugate vaccine may have limited defense against secondary pneumococcal infection after influenza infection. Therefore, until a fully protective vaccine is available, a method of increasing immunity may be helpful. Ginseng has been shown to increase the defense against influenza in clinical trials and animal experiments, as well as the defense against pneumococcal pneumonia in animal experiments. Based on these findings, ginseng is suspected to be helpful for providing immunity against COVID-19.

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

  • Jeon, Hong Bae;Yoon, Jae Hee;Lim, Nam Kyu
    • Archives of Plastic Surgery
    • /
    • 제49권3호
    • /
    • pp.310-314
    • /
    • 2022
  • The emergence of vaccines for coronavirus disease 2019 (COVID-19) raises risk of possible adverse events from interaction between the vaccines and facial aesthetic care. A 47-year-old female with no medical comorbidities visited our emergency room due to midface painful swelling after 3 hours following receiving the second dose of the messenger RNA BNT162b2 COVID-19 vaccine. About 14 years ago, she underwent nonsurgical augmentation on the nasojugal groove with a calcium hydroxylapatite dermal filler. We performed incision and drainage under general anesthesia on the next day. During operation, yellowish pus-like materials bulged out. After an operation, we performed a combination therapy with antibiotics and methylprednisolone. Her symptoms improved day by day after surgery, and then a complete recovery was achieved at 3 weeks after the treatment. In conclusion, providers of aesthetic procedures are to be aware of the potential risks of such vaccines for patients who already had or seek to receive dermal filler injections.

An autopsy case of cerebral arterial thrombosis after vaccination with ChAdOx1 nCOV-19

  • Hyeji Yang;Jaeyoon Ha;Hyun Wook Kang
    • Journal of Medicine and Life Science
    • /
    • 제19권2호
    • /
    • pp.74-77
    • /
    • 2022
  • We present a fatal case of cerebral arterial thrombosis after corona virus disease 19 (COVID-19) vaccination with ChAdOx1 nCOV-19. The deceased was a 63-year-old woman with no relevant medical history. She presented symptoms of nausea, fatigue, and headache immediately after vaccination. Ten days after vaccination, she suddenly started vomiting and developed high blood pressure. The patient eventually died 23 days after vaccination. Autopsy findings showed that the cerebral arteries and internal carotid arteries were fully enlarged and were compacted with thrombi. The brain stem showed ischemic necrosis, and extravasation from this necrotic lesion led to focal subarachnoid hemorrhage around the brain stem where large blood clots still remained. No aneurysms or atherosclerotic changes were found in these arteries. We note the following three facts. Firstly, all symptoms occurred immediately after vaccination; secondly, the main cause of death was consistent with known side effects of the vaccine; and lastly, the mechanism of thrombus formation in this case goes beyond the general category of thrombogenesis known so far. While the authors know that this case does not fall into known categories of vaccine side effects, we presenting this case to demonstrate that a comprehensive review of various possibilities related to vaccine side effects is needed to establish a COVID-19 defense system.

Antibody response to COVID-19 vaccination in patients on chronic hemodialysis

  • Heejung Choi;Sungdam Han;Ji Su Kim;Bumhee Park;Min-Jeong Lee;Gyu-Tae Shin;Heungsoo Kim;Kyongmin Kim;A-Young Park;Ho-Joon Shin;Inwhee Park
    • Clinical and Experimental Vaccine Research
    • /
    • 제12권3호
    • /
    • pp.249-259
    • /
    • 2023
  • Purpose: Since patients on hemodialysis (HD) are known to be vulnerable to coronavirus disease 2019 (COVID-19), many studies were conducted regarding the effectiveness of the COVID-19 vaccine in HD patients in Western countries. Here, we assessed antibody response of HD patients for 6 months post-vaccination to identify the duration and effectiveness of the COVID-19 vaccine in the Asian population. Materials and Methods: We compared antibody response of the COVID-19 vaccine in HD patients with healthy volunteers. Patient and control groups had two doses of ChAdOx1 nCoV-19 and mRNA-1273, respectively. Immunoglobulin G (IgG) was measured before vaccination, 2 weeks after the first dose, 2 and 4 weeks, 3 and 6 months after the second dose. Neutralizing antibody was measured before vaccination and at 2 weeks, 3 and 6 months after second dose. Since the third dose was started in the middle of the study, we analyzed the effect of the third dose as well. Results: Although antibody production was weaker than the control group (n=22), the patient group (n=39) showed an increase in IgG and neutralizing antibody after two doses. And, 21/39 patients and 14/22 participants had a third dose (BNT162b2 or mRNA-1273 in the patient group, mRNA-1273 in the control group), and it did not affect antibody response in both group. Trend analysis showed IgG and neutralizing antibody did not decrease over time. Age, sex, and HD vintage did not affect antibody production in HD patients. Patients with higher body mass index displayed better seroresponse, while those on immunosuppressants showed poor seroresponse. Conclusion: Two doses of vaccination led to significant antibody response in HD patients, and the antibody did not wane until 6 months.